Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GHSR | Q92847 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802423 | 1.00 | KMT2A (0.56) | KMT2AGHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL4802144 | 0.81 | GHSR (0.52) | KMT2AGHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL4802163 | 0.81 | GHSR (0.52) | KMT2AGHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL1845491 | 0.81 | HTR6 (0.59) | MAPTHTTSMN1; SMN2NPSR1POLB | |
| SCHEMBL4801345 | 0.81 | GHSR (0.54) | KMT2AGHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL4801336 | 0.81 | GHSR (0.54) | KMT2AGHSRMAPTHTTSMN1; SMN2 | |
| SCHEMBL3049503 | 0.79 | MAPT (0.59) | KMT2AMAPTSMN1; SMN2NPSR1POLB | |
| SCHEMBL2762828 | 0.79 | POLB (0.56) | KMT2AMAPTNPSR1POLBCTSV | |
| SCHEMBL7940000 | 0.74 | ALDH1A1 (0.57) | KMT2AMAPTHTTSMN1; SMN2NPSR1 | |
| SCHEMBL7829917 | 0.74 | MAOA (0.47) | POLBCTSVCTSLABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | KMT2A 2190/4885GHSR 1/4885MAPT 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.